AT380810T - Protein tyrosine kinase inhibitors - Google Patents

Protein tyrosine kinase inhibitors

Info

Publication number
AT380810T
AT380810T AT03757583T AT03757583T AT380810T AT 380810 T AT380810 T AT 380810T AT 03757583 T AT03757583 T AT 03757583T AT 03757583 T AT03757583 T AT 03757583T AT 380810 T AT380810 T AT 380810T
Authority
AT
Austria
Prior art keywords
tyrosine kinase
kinase inhibitors
protein tyrosine
protein
inhibitors
Prior art date
Application number
AT03757583T
Other languages
German (de)
Inventor
Wayne Danter
George Ma
Natalie Lazarowych
Stephen Houldsworth
Martyn Brown
Ghenadie Rusu
Jianhua Zhong
Original Assignee
Critical Outcome Technologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US41691102P priority Critical
Application filed by Critical Outcome Technologies filed Critical Critical Outcome Technologies
Publication of AT380810T publication Critical patent/AT380810T/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
AT03757583T 2002-10-09 2003-10-09 Protein tyrosine kinase inhibitors AT380810T (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US41691102P true 2002-10-09 2002-10-09

Publications (1)

Publication Number Publication Date
AT380810T true AT380810T (en) 2007-12-15

Family

ID=32093922

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03757583T AT380810T (en) 2002-10-09 2003-10-09 Protein tyrosine kinase inhibitors

Country Status (8)

Country Link
US (1) US7629347B2 (en)
EP (1) EP1551824B1 (en)
AT (1) AT380810T (en)
AU (1) AU2003273675A1 (en)
CA (1) CA2542007C (en)
DE (1) DE60318089T2 (en)
ES (1) ES2298563T3 (en)
WO (1) WO2004033446A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180043366A (en) 2015-09-02 2018-04-27 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 Pyridinone dicarboxamide for use as a bromo domain inhibitor
EP3353162A1 (en) 2015-09-22 2018-08-01 Glaxosmithkline Intellectual Property (No. 2) Limited Pyridinone dicarboxamide for use as bromodomain inhibitors
BR112018006545A2 (en) 2015-10-05 2018-10-16 Glaxosmithkline Ip No 2 Ltd ? compound, pharmaceutical composition, combination, use of a compound, and method for treating a disease or condition?
CN109153646A (en) * 2016-05-24 2019-01-04 葛兰素史克知识产权第二有限公司 Pyridine dicarboxamide derivatives as bromine structural domain inhibitor

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US660037A (en) * 1899-05-01 1900-10-16 Wellman Seaver Engineering Company Hot-blast stove.
DE3678805D1 (en) 1985-11-08 1991-05-23 Glaxo Group Ltd Indole derivatives.
US5155110A (en) * 1987-10-27 1992-10-13 Warner-Lambert Company Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
LU87766A1 (en) * 1990-07-20 1992-03-11 Oreal pyrimidine derivatives of use of 3-oxide to slow down hair loss and topical compositions used
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
JP3507071B2 (en) * 1991-05-01 2004-03-15 アヴェンティス ファーマシューティカルズ インコーポレイテッド Bismono- and bicyclic aryl and heteroaryl compounds inhibiting EGF and / or PDGF receptor tyrosine kinase
USRE37650E1 (en) * 1991-05-10 2002-04-09 Aventis Pharmacetical Products, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5714493A (en) * 1991-05-10 1998-02-03 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5656643A (en) * 1993-11-08 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
USRE36256E (en) * 1991-05-10 1999-07-20 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
JPH0558894A (en) 1991-08-27 1993-03-09 Kanegafuchi Chem Ind Co Ltd Antitumor agent
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
EP0600832A1 (en) 1992-11-27 1994-06-08 Ciba-Geigy Ag Derivatives of diamino benzoic and diamino phthalic acid und their use as protein linase inhibitors
US5618829A (en) * 1993-01-28 1997-04-08 Mitsubishi Chemical Corporation Tyrosine kinase inhibitors and benzoylacrylamide derivatives
US5543520A (en) * 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
WO1995009847A1 (en) * 1993-10-01 1995-04-13 Ciba-Geigy Ag Pyrimidineamine derivatives and processes for the preparation thereof
NZ278135A (en) * 1994-02-23 1998-03-25 Pfizer Nitrogen containing heterocyclically substituted quinazoline derivatives and pharmaceutical compositions
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
DE19501481A1 (en) 1995-01-19 1996-07-25 Bayer Ag 2,8-Disubstituted quinazolinones
AU5343096A (en) * 1995-04-27 1996-11-18 Zeneca Limited Quinazoline derivatives
DE69618587D1 (en) * 1995-06-07 2002-02-21 Sugen Inc Quinazolines and pharmaceutical compositions
US6265427B1 (en) * 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
US5763470A (en) * 1995-06-07 1998-06-09 Sugen Inc. Benzopyran compounds and methods for their use
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
AR004010A1 (en) * 1995-10-11 1998-09-30 Glaxo Group Ltd heterocyclic compounds
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US5760041A (en) * 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
HRP970371A2 (en) * 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
DE69716916T2 (en) * 1996-07-13 2003-07-03 Glaxo Group Ltd Condensed heterocyclic compounds as protein kinase inhibitors
PL331154A1 (en) * 1996-07-13 1999-06-21 Glaxo Group Ltd Bicyclic heteroaromatic compounds as inhibitors of proteinous tyrosine kinase
US6180636B1 (en) * 1996-08-23 2001-01-30 Novartis Ag Substituted pyrrolopyrimidines and processes for their preparation
CA2266519C (en) * 1996-10-02 2007-01-23 Novartis Ag Pyrimidine derivatives and processes for the preparation thereof
CO4940418A1 (en) * 1997-07-18 2000-07-24 Novartis Ag Crystal modification a N-phenyl-2- pyrimidinamine, processes for their manufacture and use
ZA9806729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA9806732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
JPH1180131A (en) 1997-09-01 1999-03-26 Mitsubishi Chem Corp Ethynyl pyrimidine derivatives
AT401312T (en) * 1997-12-15 2008-08-15 Astellas Pharma Inc PYRIMIDINE-5-carboxamide DERIVATIVES
US6184377B1 (en) * 1997-12-15 2001-02-06 Sepracor Inc. Compositions containing N-amino- and N-hydroxy-quinazolinones and methods for preparing libraries thereof
WO1999040056A1 (en) * 1998-02-06 1999-08-12 De Montfort University Hydroxylation activated prodrugs
AU3669199A (en) * 1998-04-29 1999-11-16 Georgetown University Methods of identifying and using hla binding compounds as hla-agonists and antagonists
US20010051628A1 (en) * 1998-05-04 2001-12-13 H.-J. Su Huang Methods to modulate the resistance of cells to apoptosis mediated by mutant epidermal growth factor receptors
US6253168B1 (en) * 1998-05-12 2001-06-26 Isis Pharmaceuticals, Inc. Generation of virtual combinatorial libraries of compounds
US6289352B1 (en) * 1998-05-29 2001-09-11 Crystal Decisions, Inc. Apparatus and method for compound on-line analytical processing in databases
US6525072B1 (en) * 1998-08-31 2003-02-25 Sugen, Inc. Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity
US6542858B1 (en) * 1998-09-14 2003-04-01 Lion Bioscience Ag Pharmacokinetic-based drug design tool and method
ES2457396T3 (en) 1998-09-29 2014-04-25 Wyeth Holdings Llc 3-Substituted cyanoquinolines as protein tyrosine kinase inhibitors
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
EP1187633A4 (en) 1999-04-08 2005-05-11 Arch Dev Corp Use of anti-vegf antibody to enhance radiation in cancer therapy
US7067046B2 (en) * 2000-08-04 2006-06-27 Essen Instruments, Inc. System for rapid chemical activation in high-throughput electrophysiological measurements
HU0203162A3 (en) 1999-08-12 2006-07-28 Wyeth Holdings Corp Madison Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer
WO2001019825A1 (en) * 1999-09-15 2001-03-22 Warner-Lambert Company Pteridinones as kinase inhibitors
EP1218360B1 (en) 1999-10-07 2008-05-28 Amgen Inc. Triazine kinase inhibitors
GB9924862D0 (en) * 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
ITMI992711A1 (en) * 1999-12-27 2001-06-27 Novartis Ag organic compounds
HN2001000008A (en) * 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals And amide compound to inhibit protein kinases pharmaceutical compositions and method of use
BR0104424A (en) * 2000-02-05 2002-01-08 Vertex Pharma Pyrazol compositions useful as inhibitors of ERK
US6313138B1 (en) * 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
US6420382B2 (en) * 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
HU0300136A2 (en) 2000-03-06 2003-05-28 Warner Lambert Co 5-alkylpyrido [2,3-d]pyrimidines tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use
GB0007657D0 (en) * 2000-03-29 2000-05-17 Celltech Therapeutics Ltd Chemical compounds
GB2372562A (en) * 2000-04-26 2002-08-28 Ribotargets Ltd In silico screening
DE10023492A1 (en) * 2000-05-09 2001-11-22 Schering Ag New 2-(((hetero)aryl-alkyl)-amino)-aza-benzamide derivatives, are VEGF receptor, KDR kinase and FLT kinase inhibitors useful e.g. for treating tumors, psoriasis, arthritis or renal or ophthalmological diseases
US6489094B2 (en) * 2000-05-31 2002-12-03 Pfizer Inc. Method and device for drug-drug interaction testing sample preparation
US7022484B2 (en) * 2000-06-08 2006-04-04 Board Of Regents, The University Of Texas System Methods for treating neuropathological states and neurogenic inflammatory states and methods for identifying compounds useful therein
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
US6620821B2 (en) * 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US20020013334A1 (en) * 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
JP2004504276A (en) * 2000-06-26 2004-02-12 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガンThe Regents Of The University Of Michigan Use of an EGF-R protein tyrosine kinase inhibitor to prevent photoaging of human skin
US6647342B2 (en) * 2000-08-07 2003-11-11 Novodynamics, Inc. Knowledge-based process for the development of materials
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
CA2424689A1 (en) * 2000-10-17 2002-04-25 Merck & Co., Inc. Orally active salts with tyrosine kinase activity
US7759323B2 (en) * 2001-05-22 2010-07-20 Eisai R & D Management Co., Ltd. Highly purified antiendotoxin compound
AT360015T (en) * 2002-07-31 2007-05-15 Critical Outcome Technologies Protein tyrosine kinase inhibitors
US20040193538A1 (en) * 2003-03-31 2004-09-30 Raines Walter L. Receipt processing system and method
CA2429907A1 (en) * 2003-05-27 2004-11-27 Cognos Incorporated Modelling of a multi-dimensional data source in an entity-relationship model

Also Published As

Publication number Publication date
EP1551824B1 (en) 2007-12-12
US7629347B2 (en) 2009-12-08
EP1551824A1 (en) 2005-07-13
WO2004033446A1 (en) 2004-04-22
US20060111371A1 (en) 2006-05-25
AU2003273675A1 (en) 2004-05-04
ES2298563T3 (en) 2008-05-16
DE60318089D1 (en) 2008-01-24
DE60318089T2 (en) 2008-12-04
CA2542007A1 (en) 2004-04-22
CA2542007C (en) 2010-06-29

Similar Documents

Publication Publication Date Title
DE60317984D1 (en) TOTAL THICK resection
DE60318867D1 (en) Solution for nail use
DE69918528D1 (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
DK1487805T3 (en) pyrimidine
DK1567522T3 (en) pyrimidine
DE60309848D1 (en) Purine derivatives as kinase inhibitors
DK1784396T3 (en) Pyrazole-substituted amino heteroaryl compounds as protein kinase inhibitors
DE60327385D1 (en) Protein stabilizer
DE60237145D1 (en) quinazoline derivatives
DK1317442T3 (en) Quinolinone derivatives as tyrosine kinase inhibitors
DE60317077D1 (en) Pyrazolopyrimidines as inhibitors cycline-dependent kinases
DK1255752T3 (en) Pyrrole-substituted 2-indolinone protein kinase inhibitors
DE50310853D1 (en) humeral
AP2114A (en) Aminoheteroaryl compounds as protein kinase inhibitors
DE60021423D1 (en) 4-substituted 7-aza-indolin-2-one and its application as protein kinase inhibitors
DE69940808D1 (en) Heterocycles substituted imidazopyrazines as protein tyrosine kinase inhibitors
DK1474420T3 (en) quinazoline
DK1499311T3 (en) Substituted benzols and their use as RAF kinase inhibitors
DE60311906D1 (en) Direct immunosensory test procedure
DE60313872D1 (en) Pyrazoloe1,5-atpyrimidines as inhibitors cycline-dependent kinases
DK1847539T3 (en) Quinazoline derivatives
DE60319158D1 (en) Pyrazoloisoquinoline derivatives as kinase inhibitors
DE60117568D1 (en) Condensed pyrazo derivatives as protein kinase inhibitors
DE60128709D1 (en) Triazol compounds as protein kinase inhibitors
AP1718A (en) 3-(4-Amidopyrrol-2-ylmethlidene)-2-indollnone derivatives as protein kinase inhibitors

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1551824

Country of ref document: EP